Study on pharmacokinetics and dosage adaptation of meropenem in pediatric patients receiving continuous hemodiafiltration

Study on pharmacokinetics and dosage adaptation of meropenem in pediatric patients receiving continuous hemodiafiltration - Pharmacokinetic study of meropenem in pediatric patients with CHDF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014904

Enrollment

Registered

2014-09-01

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 15 years old or younger 2) Patient who is treated with meropenem intravenously 3) Patient who is received continuous haemodiafiltration 4) Informed consent by the document

Exclusion criteria

Exclusion criteria: 1) Other clinical difficulties in this study

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters (clearance, volume of distribution, half life) of meropenem	—

Countries

Japan

Contacts

Public ContactKeita Hirai

school of pharmaceutical science, university of Shizuoka graduate school Department of clinical pharmacology and genetics

hiraik@u-shizuoka-ken.ac.jp054-264-5674

Outcome results